Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

There is zero evidence that ​​semaglutides can increase the size of your crown jewels. What may happen is that as you lose ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

SHREVEPORT, La. - A new drug developed by Eli Lily works in a unique way compared to treatments already on the market, like ...

Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

GLP-1 patches for weight loss have made the scene—but a leading MD warns you they aren't the same as the more familiar ...